90749-73-8

Upstream product

• 111-74-0 N,N'-diethylethylenediamine 
• 90-99-3 diphenylchloromethane 

Downstream Products

• 110480-54-1 8-(2-{[2-(Benzhydryl-ethyl-amino)-ethyl]-ethyl-amino}-ethyl)-3-isobutyl-1-methyl-3,7-dihydro-purine-2,6-dione 
• 110480-55-2 8-(2-{[2-(Benzhydryl-ethyl-amino)-ethyl]-ethyl-amino}-ethyl)-3-isobutyl-1,7-dimethyl-3,7-dihydro-purine-2,6-dione 
• 110480-56-3 8-(3-{[2-(Benzhydryl-ethyl-amino)-ethyl]-ethyl-amino}-propyl)-3-isobutyl-1,7-dimethyl-3,7-dihydro-purine-2,6-dione 

Relevant academic research and scientific papers

Quinoline derivatives

Novel heterocyclic compounds, which are represented by the following general formula, useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

New xanthine derivatives with potent and long lasting anti-bronchoconstrictive activity

Twenty eight new derivatives of 8-aminoalkyl substituted xanthine have been synthesized.They all have demonstrated a potent anti-bronchoconstrictive effect in the guinea pig and some of them have a very long duration of action (>48 h).Among them, one compound: 1-methyl 3-isobutyl 8-(4-benzhydryl piperazino ethyl)xanthine (57) (S 9795) has been selected for clinical trials in asthmatic patients because of its long duration of action, its lack of CNS stimulating effects and its inhibiting action on mast cell degranulation and phosphodiesterase activity.Keywords - 8-aminoalkyl substituted xanthines / benzhydryl piperazine / piperidine / ethylenediamine / anti-bronchoconstrictors / phosphodiesterase inhibitors / asthma